Andrew Paul Mazar - 01 Apr 2025 Form 4 Insider Report for ACTUATE THERAPEUTICS, INC. (ACTU)

Role
Chief Operating Officer
Signature
/s/ Paul Lytle, Attorney-in-Fact
Issuer symbol
ACTU
Transactions as of
01 Apr 2025
Net transactions value
$0
Form type
4
Filing time
02 Apr 2025, 13:43:25 UTC
Previous filing
12 Aug 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACTU Employee Stock Option (right to buy) Award $0 +51,046 $0.000000 51,046 01 Apr 2025 Common Stock 51,046 $6.70 Direct F1
transaction ACTU Employee Stock Option (right to buy) Award $0 +110,346 $0.000000 110,346 01 Apr 2025 Common Stock 110,346 $6.70 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Options will vest as to 25% on April 1, 2026 with the remaining 75% vesting in equal monthly installments during the 36 months following the first anniversary of the grant date.
F2 Options will vest as to 25% on August 14, 2025 with the remaining 75% vesting in equal monthly installments during the 36 months thereafter.